Repligen Corporation to Present at Evercore Healthcare Conference
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will participate in the 8th Annual Evercore Healthcare Conference taking place Dec 2–4, 2025 in Coral Gables, Florida.
Jason Garland, Chief Financial Officer, will join an analyst-led discussion on Dec 3, 2025 at 1:20 p.m. ET. A live webcast will be available on Repligen’s Investor Relations website at www.repligen.com, with a limited-time replay following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RGEN declined 0.34%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: STVN up 4.31%, TFX down 3.02%, while BLCO, ATR, and MMSI post modest gains. With no peers in the momentum scanner and no same-day peer headlines, RGEN’s action appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | -0.3% | Announcement of Evercore Healthcare Conference appearance with webcast access details. |
| Nov 04 | Conference schedule | Neutral | -2.2% | Outlined five November 2025 investor conferences with executive participation. |
| Oct 28 | Earnings results | Positive | -5.9% | Reported Q3 2025 growth with <b>$189M</b> revenue and raised 2025 guidance to <b>$729M–$737M</b>. |
| Oct 15 | Earnings preview | Neutral | +0.8% | Set date and access details for Q3 2025 financial results call and webcast. |
| Aug 22 | Conference schedule | Neutral | +4.3% | Announced three September 2025 healthcare conferences with CEO/CFO participation. |
Recent history shows strong fundamental news, including Q3 2025 revenue of $189M and raised full-year guidance to $729M–$737M, was followed by a -5.92% move, indicating a tendency for earnings-related strength to meet selling pressure. By contrast, routine conference announcements have generally seen modest, mixed price reactions.
Over the last six months, Repligen has combined steady investor-relations outreach with solid operating results. Multiple conference announcements in August, October, and November 2025 emphasized regular engagement via webcasts and analyst discussions, including today’s Evercore Healthcare Conference update. On October 28, 2025, Q3 2025 results highlighted $189M revenue, raised full-year guidance to $729M–$737M, and cash of $749M, yet the stock fell 5.92%, underscoring a pattern of selling on strong earnings. Today’s item fits the ongoing conference participation cadence.
Market Pulse Summary
This announcement highlights Repligen’s continued presence at major healthcare investor events, with the CFO scheduled for an analyst-led discussion on December 3, 2025 at 1:20 p.m. ET and webcast access via its Investor Relations site. In context, the company recently reported Q3 2025 revenue of $189M, raised full-year guidance to $729M–$737M, and held $749M in cash, while maintaining an active conference schedule that supports ongoing investor engagement.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthcare Conference, being held December 2 -4 in Coral Gables, Florida. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on December 3rd at 1:20 p.m. ET.
A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
FAQ
When will Repligen (RGEN) present at the Evercore Healthcare Conference in 2025?
Who from Repligen (RGEN) will speak at the Evercore Healthcare Conference?
How can investors watch Repligen (RGEN) presentations from the Evercore conference?
What is the schedule for Repligen’s (RGEN) analyst-led discussion at Evercore?
Where is the 8th Annual Evercore Healthcare Conference being held for Repligen (RGEN)?
Will Repligen (RGEN) make the Evercore presentation available after the live event?
